| heterogenous vaccine | Vaccine that is not autogenous, but is prepared from the same species of bacterium. (05 Mar 2000) |
|---|---|
| hib vaccine | A vaccination that is given to infants to protect against infection with haemophilus influenza b, an important cause of neonatal sepsis. Typically administered at 2, 4, 6 and 15 months. Children who are aged 15 months to 5 years, who have not received the vaccine, should be given a single injection of haemophilus b conjugate vaccine. (27 Sep 1997) |
| high-egg-passage vaccine | Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats. (05 Mar 2000) |
| Semple vaccine | A modification of the original (Pasteur) rabies vaccine, formerly widely used in the U.S., prepared from rabbit nerve tissue, inactivated with phenol and administered in 14 to 21 daily injections; has variable potency and is associated with a high incidence of postvaccinal demyelination. (05 Mar 2000) |
| smallpox vaccine | A live vaccinia virus vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (12 Dec 1998) |
| split-virus vaccine | <pharmacology> A vaccine composed of a purified antigenic determinant that is separated from the disease-causing organism. (06 Mar 1998) |
| staphylococcus vaccine | A suspension of organisms from cultures of one or more strains of Staphylococcus; used for furunculosis, acne, and other suppurative conditions. (05 Mar 2000) |
| stock vaccine | A vaccine made from a stock microbial strain, in contradistinction to an autogenous vaccine. (05 Mar 2000) |
| subunit vaccine | <pharmacology> A vaccine composed of a purified antigenic determinant that is separated from the disease-causing organism. (06 Mar 1998) |
| diphtheria-tetanus-pertussis vaccine | A vaccine consisting of diphtheria toxoid, tetanus toxoid, and pertussis vaccine. It is usually given to infants three times at two-month intervals, generally at 2, 4, and 6 months of age. The vaccine protects against diphtheria, tetanus, and whooping cough. In most cases the vaccine causes only a temporary fever and discomfort, but in a few cases serious neurological side effects have been observed. (12 Dec 1998) |
| DTP vaccine | A vaccination administered to infants for protection against diphtheria, pertussis (whooping cough) and tetanus. Vaccinations are typically administered at 2, 4, 6 and 15 months. A final vaccination is now recommended at 4-6 years of age. (27 Sep 1997) |
| duck embryo origin vaccine | See: rabies vaccine. (05 Mar 2000) |
| inactivated polio vaccine | <pharmacology, virology> An inactivated vaccination, administered by injection to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final vaccine is recommended at 4-6 years. (27 Sep 1997) |
| inactivated poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| influenza vaccine | A special vaccine which provides immunity to infection by a variety of Influenza viruses. The vaccine is updated annually due to the constant introduction of new viral strains. Flu vaccination programs are common in the elderly population and any other groups who are at increased risk of viral infection. (27 Sep 1997) |